Fully human anti-VEGF antibodies and methods of using

US8216571B2 · kind B2 · utility

Assignee

• SCHERING CORPORATION · US

Inventors

• Sumant Ramachandra · Northbrook, US
• Walter Robert Bishop · Pequannock, US
• Linda Masat · Walnut Creek, US
• Chao Bai Huang · San Leandro, US
• Toshihiko Takeuchi · Oakland, US
• Seema Kantak · Pacifica, US
• Chin-Yi Huang · Fremont, US

Key dates

• Filing date: Oct 20, 2008
• Grant date: Jul 10, 2012
• Expiry date: Oct 20, 2028

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S435/81
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.